October 21, 2014 11:23 AM ET

Pharmaceuticals

Company Overview of Prism Pharmaceuticals, Inc.

Company Overview

As of May 12, 2011, Prism Pharmaceuticals, Inc. operates was acquired by Baxter International Inc. Prism Pharmaceuticals, Inc., an acute care pharmaceutical company, engages in the development and commercialization of cardiovascular injectable products in the United States. Its products include NEXTERONE, an anti arrhythmic agent in the form of injectable amiodarone; and PM103, an intravenous formulation of clopidogrel bisulfate. The company was incorporated in 2003 and is based in King of Prussia, Pennsylvania.

1016 West Ninth Avenue

Suite 130

King of Prussia, PA 19406

United States

Founded in 2003

Phone:

610-265-7710

Fax:

610-265-7706

Key Executives for Prism Pharmaceuticals, Inc.

Prism Pharmaceuticals, Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Jennerex Biotherapeutics, Inc. United States
Marco Hi-Tech JV Ltd. United States
Polaris Pharmaceuticals, Inc. United States
Herbalife International of America, Inc. United States
Bayer HealthCare Pharmaceuticals Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Prism Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.